Lenvima

Drug - Lenvima™ (lenvatinib capsules) [Eisai Inc.]

November 2015

Therapeutic area - Oncology

Approval criteria

The patient must meet all of the following criteria:

Has a diagnosis of differentiated thyroid cancer
The disease is locally recurrent or metastatic
The disease is refractory to radioactive iodine treatment
No longer responds to TSH suppressive therapy

Quantity limit

10 mg daily dose = 30 capsules per 30 days
14 mg daily dose = 60 capsules per 30 days
20 mg daily dose = 60 capsules per 30 days
24 mg daily dose = 90 capsules per 30 days

Billing

LENVIMA is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.

Questions?

MHCP Provider Call Center 651-431-2700 or 800-366-5411